cbc.ca on MSN26d
4 drugs for rare diseases to be covered under N.B. deal with federal government
Drug coverage for four drugs used to treat some rare diseases was announced in Fredericton on Wednesday under a $32-million ...
aad.org5d
Cutaneous T-cell lymphoma: Diagnosis & treatment
Am J Hematol. 2021 Oct 1;96(10):1313-28. Jawed SI, Myskowski PL, et al. “Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome) Part II. Prognosis, management, and future directions ...
Understanding the impact of the sun on the skin
Think of your skin as a diary that keeps track of the days that you skipped sunscreen. Whenever you stepped out without sun ...
verywellhealth27d
How to Recognize Skin Lymphoma Symptoms
American Cancer Society. Key statistics for lymphoma of the skin. Lima M. Cutaneous primary B-cell lymphomas: From diagnosis to treatment. An Bras Dermatol. 2015;90(5):687-706. American Cancer Society ...
Le Lézard6d
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...
BioSpace29d
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
The primary endpoint for the study is evaluating the number ... as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful ...
Pharmaceutical Technology22d
PF-08046045 by Pfizer for Cutaneous T-Cell Lymphoma: Likelihood of Approval
PF-08046045 is under clinical development by Pfizer and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase I drugs for Cutaneous T-Cell Lymphoma have an 84% phase ...
BioSpace14d
Cutaneous Squamous Cell Carcinoma Market Size to Reach USD 14.0 Billion by 2035, Impelled by Technological Advancements in Treatment Modalities
The primary driver of this market expansion is the shift ... of 4.65% during 2024-2034. Cutaneous T-Cell Lymphoma Market: The 7 major Cutaneous T-cell-lymphoma market reached a value of US$ 428.2 ...